Key result
Dalteparin treatment produced equivalent peak steady-state antifactor Xa levels in patients with renal impairment compared to controls.
Why the study?
Does renal impairment alter peak antifactor Xa activity in patients receiving dalteparin compared to controls with normal renal function?
Observational (n=22)
Open-label
No
Does renal impairment alter peak antifactor Xa activity in patients receiving dalteparin compared to controls with normal renal function?
Peak antifactor Xa activity is equivalent in patients with and without renal impairment receiving dalteparin, suggesting dose adjustments may not be necessary for non-dialysis patients.
Answers are grounded in this paper and cite their sources.
Equivalent antifactor Xa levels with dalteparin in renal impairment; extends pharmacokinetic data but leaves clinical outcomes open.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shprecher et al. (2005) conducted an observational in Renal impairment (n=22). Dalteparin vs. Control subjects with normal renal function was evaluated on Peak steady-state antifactor Xa levels (p=0.0001). Dalteparin treatment produced equivalent peak steady-state antifactor Xa levels in patients with renal impairment compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: